Neurotoxicity and dermatotoxicity of cyanomorpholinyl adriamycin.
The highly lipophilic cyanomorpholinyl adriamycin (CMA) is the most potent antineoplastic anthracycline yet described. CNS distribution and toxicity were examined after i.v. administration of CMA to mice. At doses greater than or equal to 0.1 mg/kg, a neurotoxic syndrome including ataxia, hypokinesia, and tremors appeared. At doses of less than or equal to 0.05 mg/kg, which have been reported to be antineoplastic, no neurotoxicity was observed. On histopathologic examination, no changes were observed in the brain, spinal cord, or dorsal root ganglia. Unlike adriamycin (ADR), which rapidly appears in the nuclei of several tissues, CMA showed no fluorescence, suggesting a different cellular microcompartmentalization. The i.d. injection of CMA disclosed a 200-fold increase in toxicity compared with that of adriamycin. In comparisons of CMA and ADR, neurotoxicity and cardiotoxicity occurred equally only at higher doses; however, the dermatotoxicity and antineoplastic activity of CMA were increased several hundred-fold.
Cramer
S C
SC
Department of Biochemistry, University of Southern California, School of Medicine, Los Angeles 90033.
Rhodes
R H
RH
Acton
E M
EM
Tökés
Z A
ZA
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000032:analysis / Q000633:toxicity*; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000032:analysis / Q000633:toxicity; D005453:Fluorescence; D051379:Mice; D012867:Skin / Q000187:drug effects* / Q000473:pathology
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C038555:3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin